

Detection of *cagA* Genome in Sera of Infected Patients to *Helicobacter pylori*

Hatami Saeideh¹, Esmaeili Davoud^{2*} and Fallah Jalil²

¹Science and Research Branch, Islamic Azad University,
Department of Biology Tehran, Iran.

²Applied Microbiology Research center and Department of Microbiology,
Faculty of Medical science, Baqiyatallah University, Tehran, Iran.

(Received: 01 February 2012; accepted: 24 March 2012)

Helicobacter pylori has been associated with gastritis, peptic ulcer, and gastric adenocarcinoma. The clinical outcome of *Helicobacter pylori* infection may be associated with or without CagA. To investigate presence of CagA gene in *Helicobacter pylori* strains among patient sera about 100 serum specimens that were positive were taken. serum samples were studied using unique primers, CagA gene was investigated among the *H. pylori* strains. Among tested samples, *cagA* genome was detected in 15. PCR method was done on serum positive samples and were found that the prevalence of CagA gene in patient sera were 18% (18 from 100 cases). According to the findings, it is suggested that presence of CagA gene in strains of *Helicobacter pylori* may play an important role in aggravating disorders. In this investigation for first time in world we enable detect *cagA* genome in patient sera. *H. pylori* don't create bacteremia and septicemia but enable secret CagA protein and genome to host cells. Thus risk of integration of *cagA* genome in host cell chromosome and induction of antibodies against it to exist.

Key words: Detection, *cagA* genome, Serum.

Helicobacter pylori is one of common bacteria causing chronic infection, which infects more than half of the human population in all world, causes chronic gastritis and adenocarcinoma¹⁻⁵. *H. pylori* strains have been divided into types I and II that Type I strains express CagA and VacA but Type II strains not express these antigens^{6, 7}. It has been recommended patients that to be infected with type I strains more competence to ulcer peptic, Atherosclerosis and gastritis^{8, 9}. The *cagA* gene is part of the *cag* pathogenicity island, a 40-kb DNA region, that may be associated with secret of virulence factors. Several studies have

reported an increased prevalence of CagA-positive *H. pylori* in gastric cancer^{10, 11}. Once *H. pylori* CagA injected into gastric epithelial cells, it can alter the host cells structure, cytokines release, cycle, and gene expression^{12, 13}. The East-Asian CagA associated with increased virulence. Inactive CagA enable induce antibodies. The about 60 to 80% of *H. pylori* strains expressed CagA protein with molecular weight 120- to 128-kDa¹⁴. Serologic recognition of this protein in an ELISA is a highly specific indicator of *H. pylori* infection¹⁵. Furthermore, the presence of antibodies to CagA protein in either serum or mucosal secretions is associated with the presence of peptic ulceration¹⁶. The secretory system type IV secrete CagA protein and genome to into host cells. The numbers of studies have shown that infection by CagA-positive strains induces epithelial gastric

* To whom all correspondence should be addressed.
Tel.: +98-021- 88067969; Fax: +98-021-88039883
E-mail: esm114@gmail.com

cells to secrete increased amounts of interleukin-8, a cytokine that has a critical role in the inflammatory response of mononuclear and neutrophil cells¹⁷⁻²⁰. The aim of this study was to investigate presence of *cagA* genome in sera of infected patients to *H. pylori*.

MATERIALS AND METHODS

Serology

100 Serum samples that were positive for *H. pylori* were obtained and stored at -20°C until assayed. IgG & IgA antibodies against *H. pylori* infection were tested by enzyme-linked immunosorbent assay (ELISA). we study sera that have positive seum titers.

Synthetic primers

Single primer pair was used to amplify *H. pylori cagA* gene target fragment based on GenBank. Primers in early 828 bp of *cagA* fragment were candidate and were designed with use of DNA star program, consider conserved fragment and absence of EPITY motif. These primers was designed by us and their sequences as follows Primer forward : ATGACTAACGAAACTATTGATC and Primer reverse : TATCGCCAAGAGTGAATTTAG.

PCR was performed in a standard enzyme Taq DNA polymerase concentration 1 U/50ul reaction, Mg²⁺ 1.5mM, dNTP 200 uM each, primer 20 pmol/50ul, template DNA(5 ul serum) or 50 ng. The mixtures were incubated for 4min at 94°C for

primary denaturation, 60 sec at 94°C for secondary denaturation of the target DNA and then, annealing at 55°C for 60 sec, and extension at 72°C for 60 sec that 35 cycle was performed. The amplified products were analyzed by electrophoresis on 1% agarose gel(cinnagen) containing 0.1 g of ethidium bromide per ml in TAE buffer. The PCR product was visualized under UV light and photographed.

RESULTS

PCR amplification of *H. pylori cagA* gene


H. pylori with *cagA* fragment was amplified by PCR from the above primers and The PCR product was electrophoresed and visualized by 10 g/L agarose gel (Fig. 1). It revealed that the size of *cagA* DNA fragment amplified by PCR was 828 bp. The 15% from 100 specimens were positive for *cagA* genome (Fig. 2).

Sequence analysis of *cagA* gene of *H. pylori*

H. pylori Sequence of *cagA* DNA was analyzed with Forward Primer and Primer primer reverse using automatic sequence analyzer by Sanger dideoxy chain termination method by gene fanavaran. The result of analysis showed that the size of amplified DNA was about 828 bp (Fig. 3).

DISCUSSION

H. pylori is bacterium that express surface protein with a MW of 120-128 KD with name CagA. A dominant characteristic of this



Lane 5: Positive control, Lane 6: Negative control, Lane M: Marker 1 kb, Lane 1, 2, 3, 4: *CagA* amplified
Fig. 1. 10 g/L agarose gel electrophoresis of *cagA* DNA fragment amplified by PCR from *H. pylori*




Fig. 2. The specimens of positive for *cagA* genome of *H. pylori* in sera

protein is high antigenicity⁸. Since the 5'-end of *cagA* had contain sequence with properties of conserved regions we used PCR to amplify the 5'-end fragment of *cagA*⁹.

Several studies have shown that anti-CagA antibodies can be detected in patients infected with a *cagA* positive *H. pylori* strain¹⁹. The presence of anti-CagA antibodies correlates with aggravate disorders, and patients infected with a *cagA* positive strain were shown to be more prone for the development of clinically significant *H. pylori*-related disease¹⁶.

Approximaetly 60% of *H.pylori* isolates in the world possess the cytotoxin-associated gene A(*cagA*). Importantly, infection with *cagA*-positive strain is both highly associated with peptic ulcer




Fig. 3. *H. pylori* Sequence of amplified *cagA* DNA

disease, and the risk of developing intestinal metaplasia, atrophic gastritis and adenocarcinoma of the stomach¹⁶.

In order to research the cagA gene' existence in serum we designed the specific primers based on cagA gene sequence reported in GenBank, and successfully amplified the cagA gene of *H.pylori* by PCR. The secretory system type IV secrete CagA protein and cagA genome to into host cells. The number of studies have shown presence antibodies against CagA but so far don't reported detection of presence of cagA genome in sera of infected patients to *H.pylori*. In this investigation for first time in world we enable detect cagA genome in patient serum. Because of cagA genome in serum possible that antibodies secret against it and also may was integrated to into host cell chromosomes. *H. pylori* don't create bacteremia and septicemia but enable secret CagA protein and cagA genome into host celles. Thus may exist risk of integration of cagA genom in host cell chromosome and induction of antibodies against it that may were correlated to several disorders.

REFERENCES

1. Bruce MG, Maarros HI. Epidemiology of *Helicobacter pylori* infection. *Helicobacter* 2008;13 Suppl 1:1-6
2. Choung RS, Talley NJ. Epidemiology and clinical presentation of stress-related peptic damage and chronic peptic ulcer. *Curr Mol Med* 2008; **8**: 253-257.
3. Costa AC, Figueiredo C, Touati E. Pathogenesis of *Helicobacter pylori* infection. *Helicobacter* 2009;14Suppl 1:15-20
4. Herrera V, Parsonnet J. *Helicobacter pylori* and gastric adenocarcinoma. *Clin Microbiol Infect* 2009; **15**: 971-976
5. Maeda S, Mentis AF. Pathogenesis of *Helicobacter pylori* infection. *Helicobacter* 2007; **12** Suppl 1: 10-14.
6. Umeda M, Murata-Kamiya N, Saito Y, et al., *Helicobacter pylori* CagA causes mitotic impairment and induces chromosomal instability. *J Biol Chem* 2009; **284**: 22166-22172.
7. Sicinschi LA, Correa P, Peek RM, et al., CagA C-terminal variations in *Helicobacter pylori* strains from Colombian patients with gastric precancerous lesions. *Clin Microbiol Infect* 2009.
8. Jafarzadeh A, Mirzaee V, Ahmad-Beygi H, Nemati M, Rezayati MT. Association of the CagA status of *Helicobacter pylori* and serum levels of interleukin (IL)-17 and IL-23 in duodenal ulcer patients. *J Dig Dis* 2009; **10**: 107-112
9. Zeaiter Z, Huynh HQ, Kanyo R, Stein M. CagA of *Helicobacter pylori* alters the expression and cellular distribution of host proteins involved in cell signaling. *FEMS Microbiol Lett* 2008; **288**: 227-234
10. Hatakeyama M. The role of *Helicobacter pylori* CagA in gastric carcinogenesis. *Int J Hematol* 2006; **84**: 301-308.
11. Handa O, Naito Y, Yoshikawa T. CagA protein of *Helicobacter pylori*: a hijacker of gastric epithelial cell signaling. *Biochem Pharmacol* 2007; **73**: 1697-1702.
12. Talebkhan Y, Mohammadi M, Mohagheghi MA, et al., cagA gene and protein status among Iranian *Helicobacter pylori* strains. *Dig Dis Sci* 2008; **53**: 925-932
13. Suriani R, Colozza M, Cardesi E, et al., CagA and VacA *Helicobacter pylori* antibodies in gastric cancer. *Can J Gastroenterol* 2008; **22**: 255-258.
14. Hatakeyama M. The role of *Helicobacter pylori* CagA in gastric carcinogenesis. *Int J Hematol* 2006; **84**: 301-308.
15. Cooke CL, Huff JL, Solnick JV. The role of genome diversity and immune evasion in persistent infection with *Helicobacter pylori*. *FEMS Immunol Med Microbiol* 2005; **45**: 11-23.
16. Mardh E, Mardh S, Mardh B, Borch K. Diagnosis of gastritis by means of a combination of serological analyses. *Clin Chim Acta* 2002; **320**: 17-27.
17. Ye W, Held M, Enroth H, et al., Histology and culture results among subjects with antibodies to CagA but no evidence of *Helicobacter pylori* infection with IgG ELISA. *Scand J Gastroenterol* 2005; **40**: 312-318.
18. Choi KD, Kim N, Lee DH, et al., Analysis of the 3' variable region of the cagA gene of *Helicobacter pylori* isolated in Koreans. *Dig Dis Sci* 2007; **52**: 960-966.
19. Esmacili D, Mohabati Mobarez A, Hatef Salmanian A, Zavarani H.A, Hosseini doust R. Immune Responses of Conserved 32 KD fragment from N-terminal of *H. pylori* cagA gene. *J Pure Appl Microbio*, 2009; **4**(1): 117-123.
20. Zhang MJ, He LH, Wong BC, Zhou ZF, Zhang JZ. [Distribution of cagA 3' region, iceA, vacA and HP0519 on *Helicobacter pylori* isolated from China]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2006; **27**:508-512.